<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Patients with <z:hpo ids='HP_0005542'>prolonged clotting times</z:hpo> caused by <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) are at risk for <z:mp ids='MP_0005048'>thrombosis</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>This paradoxal association is not understood </plain></SENT>
<SENT sid="2" pm="."><plain>LAC is frequently caused by anti-beta2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta 2GPI) antibodies </plain></SENT>
<SENT sid="3" pm="."><plain>Antibody-induced dimerization of beta 2GPI increases the affinity of beta 2GPI for <z:chebi fb="1" ids="16247">phospholipids</z:chebi>, explaining the observed <z:hpo ids='HP_0005542'>prolonged clotting times</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>We constructed dimers of beta 2GPI that mimic effects of beta 2GPI-anti-beta 2GPI antibody complexes, and we studied their effects on platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation in a flow system </plain></SENT>
<SENT sid="5" pm="."><plain>Dimeric beta 2GPI increased platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to collagen by 150% and increased the number of large aggregates </plain></SENT>
<SENT sid="6" pm="."><plain>We also observed increased platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to collagen when whole blood was spiked with patient-derived polyclonal anti-beta 2GPI or some, but not <z:hpo ids='HP_0000001'>all</z:hpo>, monoclonal anti-beta 2GPI antibodies with LAC activity </plain></SENT>
<SENT sid="7" pm="."><plain>These effects could be abrogated by inhibition of <z:chebi fb="0" ids="26995">thromboxane</z:chebi> synthesis </plain></SENT>
<SENT sid="8" pm="."><plain>A LAC-positive monoclonal anti-beta 2GPI antibody, which did not affect platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, prevented the induced increase in platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> by beta 2GPI dimers </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, increased platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> disappeared after preincubation with receptor-associated protein, a universal inhibitor of interaction of ligands with members of the <z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> receptor family </plain></SENT>
<SENT sid="10" pm="."><plain>Using co-immunoprecipitation, it was shown that dimeric beta 2GPI can interact with <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> E receptor 2 (apoER2'), a member of the <z:chebi fb="2" ids="39026">low density lipoprotein</z:chebi> receptor family present on platelets </plain></SENT>
<SENT sid="11" pm="."><plain>These results demonstrate that dimeric beta 2GPI induces increased platelet <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> and <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation, which depends on activation via apoER2' </plain></SENT>
</text></document>